These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1715919)

  • 21. Effect of exercise, DDAVP, and epinephrine on the factor VIII:C/von Willebrand factor complex in normal dogs and von Willebrand factor deficient Doberman pinscher dogs.
    Meyers KM; Wardrop KJ; Dodds WJ; Brassard J
    Thromb Res; 1990 Jan; 57(1):97-108. PubMed ID: 2105540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DDAVP-induced increases in coagulation factor VIII and von Willebrand factor in the plasma of conscious dogs.
    Johnson GS; Kraus KH; Turrentine MA; Dean PW
    J Vet Pharmacol Ther; 1986 Dec; 9(4):370-5. PubMed ID: 3100823
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo potentiation of corticotropin releasing factor activity by vasopressin analogues.
    Fischman AJ; Moldow RL
    Life Sci; 1984 Sep; 35(12):1311-9. PubMed ID: 6332965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacology of oxytocin-(1-6)-hexapeptide amide, vasopressin-(1-6)-hexapeptide amide and their deamino analogues.
    Krejcí I; Barth T; Kupková B; Fruhaufová L; Flegel M; Zaoral M
    Eur J Pharmacol; 1973 Nov; 24(2):179-82. PubMed ID: 4797284
    [No Abstract]   [Full Text] [Related]  

  • 25. Factor VIII response to vasopressin in nephrogenic diabetes insipidus.
    D'Avanzo M; Toraldo R; Fazzone A; Papa ML; Santinelli R; Tolone C; Iafusco F
    J Pediatr; 1991 Sep; 119(3):504. PubMed ID: 1908896
    [No Abstract]   [Full Text] [Related]  

  • 26. Role of the vasoconstrictor and antidiuretic activities of vasopressin in inhibition of renin secretion in conscious dogs.
    Schwartz J; Reid IA
    Am J Physiol; 1986 Jan; 250(1 Pt 2):F92-6. PubMed ID: 3510566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Properties of rat anterior pituitary vasopressin receptors: relation to adenylate cyclase and the effect of corticotropin-releasing factor.
    Gaillard RC; Schoenenberg P; Favrod-Coune CA; Muller AF; Marie J; Bockaert J; Jard S
    Proc Natl Acad Sci U S A; 1984 May; 81(9):2907-11. PubMed ID: 6326152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of propranolol, barbiturate anesthesia and splenectomy on factor VIII:C and plasminogen activator release induced by DDAVP. An experimental study on the dog.
    Pina-Cabral JM; Cunha-Monteiro A; Sousa-Dias MC; Andrade JA
    Thromb Haemost; 1989 Sep; 62(2):784-7. PubMed ID: 2510352
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunoassay for lysine 8 -vasopressin (LVP): comparison of biological and immunological activity of lysine-vasopressin and some of its synthetic analogues.
    Marchetti J
    Experientia; 1973 Mar; 29(3):351-3. PubMed ID: 4122649
    [No Abstract]   [Full Text] [Related]  

  • 30. Molecular docking-based study of vasopressin analogues modified at positions 2 and 3 with N-methylphenylalanine: influence on receptor-bound conformations and interactions with vasopressin and oxytocin receptors.
    Slusarz MJ; Sikorska E; Slusarz R; Ciarkowski J
    J Med Chem; 2006 Apr; 49(8):2463-9. PubMed ID: 16610789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of modified electroconvulsive therapy on vasopressin release and haemostasis in man.
    Hampton KK; Grant PJ; Boothby M; Dean HG; Davies JA; Prentice CR
    Blood Coagul Fibrinolysis; 1990 Aug; 1(3):293-7. PubMed ID: 2129414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hemodynamic effects of exogenous and endogenous vasopressin at low plasma concentrations in conscious dogs.
    Montani JP; Liard JF; Schoun J; Möhring J
    Circ Res; 1980 Sep; 47(3):346-55. PubMed ID: 7408117
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vasopressins and factor VIII release.
    Grant PJ; Davies JA; Prentice CR
    Lancet; 1985 Jul; 2(8448):224. PubMed ID: 2862414
    [No Abstract]   [Full Text] [Related]  

  • 34. Stimulation of adrenocorticotropin/beta-endorphin release by synthetic ovine corticotropin-releasing factor in vitro. Enhancement by various vasopressin analogs.
    Knepel W; Homolka L; Vlaskovska M; Nutto D
    Neuroendocrinology; 1984 May; 38(5):344-50. PubMed ID: 6328345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potent vasopressin antagonists lacking the proline residue at position 7.
    Ali FE; Bryan W; Chang HL; Huffman WF; Moore ML; Heckman G; Kinter LB; McDonald J; Schmidt D; Shue D
    J Med Chem; 1986 Jun; 29(6):984-8. PubMed ID: 2940368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Binding of factor VIII inhibitors to discrete regions of the factor VIII C2 domain disrupt phospholipid binding.
    Lewis DA; Moore KD; Ortel TL
    Blood Coagul Fibrinolysis; 2003 Jun; 14(4):361-8. PubMed ID: 12945878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antidiuretic agonism and antagonism of some O-alkylated analogues of vasopressin containing 2-O-alkylated tyrosine.
    Melin P; Lundin S; Vilhardt H; Lindeberg G; Larsson LE; Pliska V
    Eur J Pharmacol; 1980 Oct; 67(2-3):173-7. PubMed ID: 7461030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of rat kidney adenylate cyclase by vasopressin analogues: lack of correlation with antidiuretic activity.
    Barth T; Rajerison MR; Roy C; Jard S
    Mol Cell Endocrinol; 1975 Jan; 2(2):81-90. PubMed ID: 1149917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of some activities of arginine vasopressin and lysine vasopressin on kidney function in conscious dogs.
    ALI MN
    Br J Pharmacol Chemother; 1958 Jun; 13(2):131-7. PubMed ID: 13536276
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Solution structure of conformationally restricted vasopressin analogues.
    Trzepałka E; Oleszczuk M; Maciejczyk M; Lammek B
    Acta Biochim Pol; 2004; 51(1):33-49. PubMed ID: 15094823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.